Xu Zhenyu 4

What Happened

• Xu Zhenyu, Chief Scientific Officer of SOPHiA GENETICS (SOPH), received equity awards on April 2, 2026: 112,936 restricted stock units (RSUs) and 164,671 derivative awards (stock option-type grant). Both were reported at $0.00 per share (no cash paid at grant). Combined, the awards total 277,607 units; actual economic value will depend on SOPH's share price at vesting or exercise. These are grants (company compensation), not open-market purchases or sales.

Key Details

• Transaction date: April 2, 2026; Form 4 filed April 3, 2026 (appears timely).
• Grant details and vesting:
  • RSUs (112,936): each RSU equals a contingent right to one ordinary share. 25% vests April 2, 2027; remaining 75% vests in equal quarterly installments through April 2, 2030. (Footnote F1)
  • Derivative award (164,671): described as a share option; 25% vests April 2, 2027, then in equal monthly installments through April 2, 2030. (Footnote F2)
• Price reported: $0.00 per unit at grant (typical for compensation awards).
• Shares owned after transaction: not provided in the information supplied.
• No indication of a 10b5-1 plan, tax-withholding sale, or immediate cashless exercise in the filing excerpt.

Context

• These awards are standard equity compensation intended to retain executives and tie pay to future performance; they do not represent an immediate buy or sell of existing shares. RSUs convert to shares only as they vest; the derivative award vests over time and would typically require exercise (and potentially payment of an exercise price, if applicable) before generating shares. For investors, awards signal management compensation alignment but do not on their own indicate buying/selling sentiment.